Medicare Advantage Plans Shrink Coverage as Millions Face Terminations in 2027
Major Medicare Advantage insurers are significantly reducing their service areas and plan offerings for 2027, with only Molina fully exiting mainstream MA coverage while others continue through specialized plans. An estimated 3 million or more beneficiaries will experience plan terminations as insurers pare back supplemental benefits like dental coverage to maintain investor-demanded profit margins. The number of available MA prescription drug plan options is declining from 32 in 2026 to 28 in 2027, limiting choices for seniors despite insurers' claims that core benefits remain intact.
The Medicare Advantage market is experiencing significant consolidation heading into 2027. While most major insurers are maintaining a presence in the program, they are strategically retreating from less profitable service areas while expanding in others. Molina's complete exit from mainstream MA coverage represents the most dramatic shift, though the company will continue serving specialized populations through targeted plans. This reshuffling reflects broader industry dynamics as insurers balance competitive pressures with shareholder expectations.
The scaling back of supplemental benefits illustrates the financial pressures facing MA plans. Dental coverage and Part B cost-sharing reductions—features that have made Medicare Advantage attractive to beneficiaries—are being reduced or eliminated. Simultaneously, prescription drug plan options are contracting, with beneficiaries having access to four fewer plan choices in 2027 compared to the previous year, potentially limiting their ability to find plans matching their medication needs.
These changes could significantly impact millions of seniors, particularly those in counties experiencing plan exits who may face disrupted care relationships or forced plan switches. Reduced supplemental benefits may increase out-of-pocket costs for vulnerable populations relying on dental coverage. Fewer prescription drug plan options could limit beneficiaries' ability to find affordable medication solutions. However, insurers maintain that core medical benefits remain accessible, suggesting the impact may be uneven across income levels and geographic regions.